Buy Crypto Markets Spot FuturesBTC Earn Event Centre Rewards Hub

Halozyme Therapeutics, Inc. (HALO)

NASDAQ

$106.75

$+0.51

(+0.48%)

Pre-Market

Halozyme Therapeutics, Inc. (HALO) Live Price Chart

Last updated: ⁦2026-09-16 09:05:00⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Halozyme Therapeutics, Inc. (HALO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $106.75, with a market capitalisation of $12.25B and a P/E ratio of 29.16. Over the past 52 weeks, its price has ranged from $61.23 to $111.15. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$12.25B
Open	$106.24
Day's High	$111.15
Day's Low	$2.60
Previous Close	$106.25
Volume	217.00
Average Volume	1.94M
P/E Ratio	29.16
52-Week High	$111.15
52-Week Low	$61.23
Dividend Yield	--
Earnings Date	--

Halozyme Therapeutics, Inc. (HALO) Pre-Market Stock Price

Halozyme Therapeutics, Inc. (HALO) is trading at $106.75 in pre-market trading as of 2026-09-16 08:39:00, up 0.47% ($0.50) from the previous close of $106.25

Pre-market trading shows how investors are pricing HALO before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.

Halozyme Therapeutics, Inc. (HALO) 7-Day Stock Price Change

Over the past seven days, Halozyme Therapeutics, Inc. (HALO) moved from $110.19 to $106.75, representing a decline of 3.12% ($3.44).

The stock traded between $105.00 and $111.15 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.

The average daily volume was 1.24 million shares, down versus the previous seven-day period, indicating lower trading activity.

HALO 52-Week Price Position

Position in Range: 91.2%

52W Low$61.23

52W High$111.15

HALO is currently trading at $106.75, placing it 91.2% of the way from its 52-week low of $61.23 to its 52-week high of $111.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Halozyme Therapeutics, Inc. (HALO)?

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	423
Exchange	NASDAQ
Company Website	https://www.halozyme.com

How to Buy Halozyme Therapeutics, Inc. (HALO) Stock on MEXC

Eligible investors can buy real shares of Halozyme Therapeutics, Inc. (HALO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licenced broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for HALO and Place Your Order

Open the RealStocks trading page and search for HALO. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Halozyme Therapeutics, Inc. (HALO) stock price today?

Halozyme Therapeutics, Inc. (HALO) is currently trading at $ 106.75, up 0.47% ($0.50) from the previous close of $ 106.25. Intraday prices update in real time during regular trading hours.

2.Is HALO stock going up or down today?

As of 2026-09-16 08:39:00, HALO is trading at $ 106.75, up 0.47% ($0.50) from its previous close of $ 106.25. The stock has traded between $ 2.60 and $ 111.15 during today’s regular session. Past price movements do not guarantee future results.

3.What is HALO pre-market price?

As of 2026-09-16 08:39:00, HALO is trading at $ 106.75 in pre-market trading, up 0.47% ($0.50) from the previous close of $ 106.25. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is HALO after-hours price?

As of 2026-09-16 08:39:00, HALO is trading at $ 106.24 in after-hours trading, down 0.01% ($0.01) from the regular-session close of $ 106.25. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is HALO stock trading now?

HALO trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does HALO sit relative to its 52-week high and low?

Over the past 52 weeks, HALO has traded between a low of $ 61.23 and a high of $ 111.15. At $ 106.75, the stock is positioned 91.2% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Halozyme Therapeutics, Inc. in?

Halozyme Therapeutics, Inc. (HALO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Halozyme Therapeutics, Inc.'s market capitalisation and where is it listed?

Halozyme Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalisation of $ 12.25B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is HALO valued in terms of P/E ratio and EPS?

HALO trades at a P/E ratio of 29.16, based on trailing-twelve-month EPS of $ 3.64. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Halozyme Therapeutics, Inc. pay a dividend?

Halozyme Therapeutics, Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.